Abstract 1524P
Background
Phase III studies (SPOTLIGHT and GLOW) showed that combining anti-Claudin18.2 (CLDN18.2) antibody with chemotherapy significantly improved outcomes for first-line treatment for G/GEJ cancer with high CLDN18.2 expression. TST001 is a potential best-in-class antibody with improved CLDN18.2 affinity and enhanced ADCC effect, leading to anti-tumor activity in low to medium CLDN18.2 expression gastric cancer animal models.
Methods
Cohort C from Transtar102 study was designed to explore the safety and efficacy of TST001 plus CAPOX as 1st- line treatment in advanced G/GEJ cancer (NCT04495296–study Transtar102). Positive CLDN18.2 (membranous staining intensity ≥1+ in ≥10% of tumor cells) assessed centrally using the IHC 14G11 LDT assay was required in the expansion phase only.
Results
As of 21 April 2023, 64 patients have been dosed with TST001 plus CAPOX, including 15 patients who received TST001 at doses ranging from 1 to 8 mg/kg Q3W in the dose escalation phase and 49 patients at 6 mg/kg in the dose expansion phase. The median follow-up is 197.5 days. The most common treatment related adverse events are nausea (70.3%), vomiting (53.1%) and hypoalbuminemia (75%) with grade 3 being 1.6% each. 42 out of the 49 patients in the 6 mg/kg expansion cohort have measurable lesions and had at least one post-treatment tumor assessment, with 28 (66.7%) achieving partial response (confirmed and unconfirmed). Across all doses, the objective response rate (confirmed and unconfirmed) is 65.4%, the estimated median progression-free survival is 9.5 months, and the estimated median duration of response is 9.9 months. 38 of 49 patients are CLDN18.2 positive with no notable difference in efficacy per CLDN18.2 level. Overall survival is immature and will be updated at the time of the conference.
Conclusions
TST001 plus CAPOX as first-line treatment for patients with G/GEJ cancer demonstrated good safety and tolerability. Encouraging anti-tumor activities have been observed regardless of the CLDN18.2 expression levels, including expression as low as ≥10% tumor cells staining ≥1+, <40% tumor cells staining <2+ or 3+. Overall survival data will be presented.
Clinical trial identification
NCT04495296.
Editorial acknowledgement
Legal entity responsible for the study
Suzhou Transcenta Therapeutics Co, Ltd.
Funding
Suzhou Transcenta Therapeutics Co, Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1508TiP - The 1920-EORTC-BIORADON study: Molecular characterization of non-small cell lung cancer (NSCLC) and indoor radon exposure in Europe
Presenter: Laura Mezquita
Session: Poster session 21
1509TiP - The 1825-EORTC, ALKALINE: Activity of lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with second generation ALK inhibitor
Presenter: Laura Mezquita
Session: Poster session 21
1510TiP - Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant non-small cell lung cancer (NSCLC) according to TP53 mutational status (TEMPLE-2/NCT05785208)
Presenter: Antonio Vitale
Session: Poster session 21
1515P - Maintenance rucaparib after first-line platinum-based chemotherapy in advanced esophagogastric (OG) adenocarcinoma: Interim results from the PLATFORM trial
Presenter: Anderley Gordon
Session: Poster session 21
1518P - Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a phase Ib/II study
Presenter: Keun-Wook Lee
Session: Poster session 21
1520P - Perioperative treatment in resectable gastric cancer with spartalizumab combined with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT): The GASPAR phase II trial
Presenter: Melanie Dos Santos
Session: Poster session 21